Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Microbiota 16 - October 2022
  3. Gut Microbiota # 16
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 16 - October 2022
  3. Gut Microbiota # 16
Gastroenterology

Gut Microbiota # 16

Fecal transplant

By Pr. Satu Pekkala
Academy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of Jyväskylä, Finland

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

Microbiota 16 Gut microbiota

About this article

Created 05 October 2022
Updated 17 January 2023

CROSS-COHORT GUT MICROBIOME ASSOCIATIONS WITH IMMUNE CHECKPOINT INHIBITOR RESPONSE IN ADVANCED MELANOMA 

Lee KA, Thomas AM, Bolte LA, et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med 2022; 28: 535-44.

Immune checkpoint inhibitors (ICIs) have significantly improved the treatment of advanced melanoma. However, not all patients respond to the treatment, which has been thought to be linked to the gut microbiota. Lee et al. performed metagenome shotgun sequencing of fecal samples from five European ICI-naïve cohorts, with a total of 165 advanced cutaneous melanoma patients. Due to clinical and mutational differences between the cohorts, they were analyzed separately and not pooled. The authors found a significant difference in the gut microbiota composition between responders and non-responders in the PRIMM-UK cohort, but not in the PRIMM-Netherland (NL) cohort. Further, by analyzing publicly available databases (n = 147 metagenomic samples), it became evident that there was limited reproducibility of response predictions across cohorts. No single bacterium was an entirely constant biomarker of response to ICIs across all datasets. However, a panel of microbial species, including Bifidobacterium pseudocatenulatum, Roseburia spp. and Akkermansia muciniphila, was identified in the study associated with responders. Regarding the functional genes of the microbiota, e.g., DNA adenine methylases were increased in the responders. In conclusion, though a potential panel of microbial biomarkers showing the responsiveness to ICI treatment was identified, future studies in larger cohorts are needed. In addition, several clinical factors should be considered as confounding when evaluating the biomarkers that may be useful in diagnostics

INTESTINAL AKKERMANSIA MUCINIPHILA PREDICTS CLINICAL RESPONSE TO PD-1 BLOCKADE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER

Derosa L, Routy B, Thomas Am et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med 2022; 28: 315-24.

Many patients with non-small-cell lung cancer (NSCLC) do not respond to the treatment with immune checkpoint inhibitors (ICIs), such as anti-PD-1. Recent evidence shows that certain members of the gut microbiota, especially Akkermansia muciniphila, can influence the efficacy of ICIs in patients with NSCLC. In addition, the treatment resistance has been associated with lower inflammatory tumor microenvironment. Derosa et al. prospective, multicentric study included 338 patients with advanced NSCLC treated with ICIs to determine whether the gut microbiota metagenome profiles could explain the treatment response. They show that higher Akkermansia abundance in the baseline feces was associated with higher response rate to the ICI treatment, associated with clinical benefit (increase in survival). In addition, the presence of Akkermansia associated with other potentially prognosis- relevant shifts in the gut microbiota. Several differentially expressed tumor genes were linked to the response to PD-1 blockade suggesting that Akkermansia could promote migration of T helper cells to the tumor microenvironment. To ultimately show that Akkermansia could rescue the ICI resistance, the authors inoculated two different strains of A. muciniphila to mice that were previously transplanted with feces of a patient with resistance to PD-1 blockade. Compared to the control mice, the two strains rescued the treatment response. By far, this study is the largest metagenomics prospective analysis that has validated Akkermansia as a potential prognostic factor for ICI-treated NSCLC patients and showed the mechanistic potential of Akkermansia.

FAECAL MICROBIOTA TRANSPLANTATION FOR BIPOLAR DISORDER: A DETAILED CASE STUDY

Parker G, Spoelma MJ, Rhodes N. Faecal microbiota transplantation for bipolar disorder: A detailed case study. Bipolar Disord 2022 (ahead of print).

The only validated indication for FMT is recurrent Clostridioides difficile infection, However, the involvement of gut microbiota in numerous other diseases (Parkinson disease for example) suggests that indications for FMT could soon be expanded.Gut microbiota can also modify numerous depression-associated processes, such as hypothalamic- pituitary-adrenal gland axis. So far, there are no published trials using FMT to treat patients with bipolar conditions. The longitudinal study by Parker et al. presents the case of a 28-year-old male with bipolar disorder. At the age of 10, he developed depressive episodes. Symptoms included a severely depressed mood, suicidal thoughts, anergia, impaired concentration, psychomotor retardation, and insomnia. The symptoms were commonly associated with irritability and anxiety. At the age of 15, he developed his first hypomanic episode. For years, he was successfully treated with drugs, but then mood problems occurred again. He voluntarily started taking probiotics (strains of Lactobacillus and Saccharomyces. After the probiotics, he self-reported a huge relief of symptoms. Encouraged by the improvements, the patient read on microbiome research and elected to trial FMT. This procedure was performed via colonoscopy by a gastroenterologist. After the FMT, he charted his mood states for 470 consecutive days. He self-reported that mood episodes decreased in frequency and severity over the months. He was also able to reduce the drug treatment significantly. Twelve months after FMT, he stated having distinct highs, virtually no bipolar symptoms, and attention deficit hyperactivity disorder symptoms had improved. Though this is only a case study, FMT was able to reduce the bipolar symptoms, thus warranting the need for FMT studies in larger bipolar cohorts.

Tags
Gut microbiota Lung cancer Gastroenterology Fecal Transplant

en_view en_sources

    Focus
    Microbiota 16 - October 2022
    • Overview
      • Gut microbiota and stress-related disorders
      • The interaction between the oral microbiota and SARS-COV-2 infection
    • Commented article
      • Immune regulation by fungal strain diversity in inflammatory bowel disease
      • Bacteroidota and Lachnospiraceae integration into the gut microbiome at key time points in early life are linked to infant neurodevelopment
    • Congress review
      • Highlights from the 54th Espghan
    • Press review
      • Gut Microbiota # 16
      • Vaginal Microbiota # 16
    • Expert opinion
      • Association between IBD and greater amounts of microplastics in stool
    Created 05 October 2022
    Updated 17 January 2023

    About this article

    To know more about this topic.

    Main topic

    Fecal transplant

    Content type

    Press review
    Highlights from the 54th Espghan
    Vaginal Microbiota # 16
    Focus

    Microbiota 16 - October 2022

    Overview

    Gut microbiota and stress-related disorders The interaction between the oral microbiota and SARS-COV-2 infection

    Commented article

    Immune regulation by fungal strain diversity in inflammatory bowel disease Bacteroidota and Lachnospiraceae integration into the gut microbiome at key time points in early life are linked to infant neurodevelopment

    Congress review

    Highlights from the 54th Espghan

    Press review

    Gut Microbiota # 16 Vaginal Microbiota # 16

    Expert opinion

    Association between IBD and greater amounts of microplastics in stool
    Gastroenterology
    L’axe intestin-cerveau dans le stress lié à la discrimination
    20.03.2023

    The gut-brain axis and discrimination-related stress

    Read the article
    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Human milk nutrient fortifiers alter the developing gastrointestinal microbiota of very-low-birth-weight infants

    Commented article - Children's section By Pr. Emmanuel M...

    Find out more

    Impact of beer and non alcoholic consumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    L’axe intestin-cerveau dans le stress lié à la discrimination
    20.03.2023

    The gut-brain axis and discrimination-related stress

    Read the article
    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo